Mannheim (Germany), October 2024: At the upcoming CPHI Milan trade show (8–10 October 2024), BENEO — in collaboration with parent company Südzucker AG — will be showcasing the taste-enhancing benefits of its proven ingredient. Visitors from the pharmaceutical industry are invited to visit Booth 6C57 at Italy’s Fiera Milano to discover how BENEO’s agglomerated pharmaceutical excipient galenIQ™ can be incorporated into a variety of oral solid dosage (OSD) forms.
In both the nutraceutical and pharmaceutical markets, demand for palatable dosage forms such as sachets and medicated candies/gummies is on the rise. “For these types of products,” observes Oliver Luhn, Head of Pharmaceutical Technology at BENEO, “palatability plays a significant role. Combining an appealing taste profile with excellent technical properties can make a huge difference. As a result, we’re seeing growing market interest in easy-to-process products such as our bulk sweetener galenIQ™.”
In addition, galenIQ™ is a versatile solution that can be used in a wide variety of applications. Michael Black, Head of Sales Pharma at BENEO, invites interested parties to the booth to learn more about products that have been formulated with the company’s filler-binder, such as chewable tablets, medicated compressed lozenges and high boiled lozenges, sachets and more.
“We’re keen to discuss how galenIQ™ can address sensory challenges in the development process, such as bitter notes associated with many active pharmaceutical ingredients or formulations containing herbal extracts, thus contributing to an improved flavour profile,” adds Black.
Formulating for a better patient experience
Derived from sugar beet, galenIQ™ has a sweetening profile that’s almost equal to sucrose (while being non-cariogenic). BENEO‘s excipient also scores when it comes to functional properties such as excellent flow/mixing properties and high compactability, all of which contribute to the stability of pharmaceutical OSDs. From a quality control perspective, galenIQ™ is manufactured according to GMP standards for pharmaceutical excipients and various grades are available to suit different dosage forms.
Maj-Britt Cepok, Head of Business Development Pharma at BENEO, commented: “On the one hand, dosage forms are getting more diverse. On the other hand, in line with a more consumer-centric approach, there’s a stronger focus on how to make taking medicines as comfortable and convenient as possible. An appealing flavour can have a significant influence on patient compliance and, with galenIQ™, manufacturers have access to a reliable solution that can help them to achieve a well-balanced sensory profile.”
About galenIQ™
BENEO is part of the Südzucker Group and a member of the International Pharmaceutical Excipients Council (IPEC). The company produces galenIQ™ (Isomalt Ph. Eur., BP, USP-NF, JP), a multifunctional range of water-soluble filler-binders, according to cGMP conditions for pharmaceutical excipients. galenIQ™ is available in a wide variety of median particle sizes, morphologies and solubilities, and is therefore readily used in solid and liquid dosage forms such as tablets, sachets, effervescents, lozenges and syrups. It is physically and chemically stable, non-hygroscopic and enhances the palatability of the final form.